Introduction
Elevated blood pressure (BP) is the most important risk factor for cardiovascular mortality and morbidity. [1] [2] [3] A continuous association between high BP and increased cardiovascular risk has been proven in both men and women throughout a wide range of ages. 4, 5 The recently announced 2017 ACC/AHA guideline adopted lower BP criteria for the definition of hypertension, from the previous 140/90 mmHg to 130/80 mmHg. 6, 7 While the 2018 ESC/ESH guidelines for the management of arterial hypertension maintained hypertension definition as BP > _140/90 mmHg, there have been changes in recommendations for high normal BP (130-139/85-89 mmHg) in that drug treatment may be considered when cardiovascular risk is very high. 8 There are debates regarding the relationship between BP and cardiovascular risk. The first is whether a J-curve association exists between cardiovascular risk and systolic and diastolic BP. Epidemiologic evidence has demonstrated that BP has a linear relationship with cardiovascular risk down to as low as 115/75 mmHg. 5, 9 Paradoxical findings have been witnessed where cardiovascular risk was elevated with an extremely low systolic BP. 10, 11 While there is no doubt that a markedly low BP is harmful, it is still unclear how low the threshold is among ambulatory healthy untreated subjects. The second debate concerns the relative importance of systolic and diastolic BP in cardiovascular risk prediction. While systolic BP is the most important component of BP, the association of diastolic BP with cardiovascular risk has not been consistent after adjustment or stratification for systolic BP. 12, 13 It has been suggested that a higher pulse pressure is associated with an increased cardiovascular risk independent of systolic and diastolic BP. 14 There are controversies regarding the use of a diastolic BP threshold in defining hypertension and initiating treatment. 15 In this study, we evaluated the association of systolic and diastolic BP with major cardiovascular events to answer the questions above. Studies evaluating clinical outcomes of BP are frequently prone to bias caused by antihypertensive medical treatment during follow-up. Subjects who were naïve to antihypertensive medication and free from previous history of cardiovascular disease were chosen from a nationwide population-based cohort and followed until the initiation of medical treatment. By linking the individual's BP data with medical claims and mortality records, we were able to estimate the natural course of untreated BP.
Methods

Data sources
We used a database provided by the National Health Insurance ServicesHealth Screening (NHIS-HEALS) Cohort in Korea. The insurance system was established by the Korean government and covers approximately 97.2% of residents. Enrolees aged 40 years or older are entitled to a general health screening programme every 2 years. The screening includes standardized self-reporting questionnaires on medical history and lifestyle behaviours, anthropometric and BP measurements, and routine laboratory tests using blood and urine. The cohort profile of the NHIS-HEALS is described elsewhere. 16 Briefly, the cohort includes 514 866 participants who underwent health screening in 2002 and 2003. Healthcare service claims data including inpatient and outpatient usage records and prescription records, as well as vital status and specific causes of death are also included in the database. This study was exempt from review by the Seoul National University Bundang Hospital Institutional Review Board (I-2018-150).
Study population
A total of 290 600 individuals aged 40 years or above who underwent a general health screening programme were extracted from the NHIS-HEALS cohort after excluding those who had (i) received antihypertensive medical treatment, (ii) experienced stroke, myocardial infarction, or heart failure before BP measurements, and (iii) BP outliers (systolic BP >250 mmHg or diastolic BP >150 mmHg). Individuals were followed up until death from any cause or the end of the cohort (December 2013), and censored when antihypertensive medical treatment was initiated.
Blood pressure and endpoint
During the study period, BP was measured using either sphygmomanometers or oscillometric devices. Blood pressure measurements were recommended to be performed after 3-5 min of rest. It was recommended to choose a cuff of appropriate size, and to repeat BP measurements > _2 times at 1-to 2-min intervals. The primary endpoint was major cardiovascular events, which was a composite of cardiac death, myocardial infarction, stroke, and heart failure. Secondary endpoints included all-cause death and each component of the primary endpoint. Vital status and the cause of death were confirmed via mortality records from the National Statistical Office of Korea. The definition of each endpoint was described in a previous study. 17 Safety endpoints included syncope and hip fracture (Supplementary material online, Methods).
Statistical analysis
Summary statistics are reported as means ± standard error for normally distributed continuous variables and as numbers (percentages) for categorical variables. Kaplan-Meier survival curves were constructed and compared using the log-rank test. Cox proportional-hazard models were used to evaluate the associations between levels of baseline BP and the risk for cardiovascular events. Hazard ratios (HRs) are presented with 95% confidence intervals (CIs) and were adjusted for (i) age and sex, and (ii) potential confounders including age, sex, body mass index, income level, diabetes, dyslipidaemia, malignancy, renal disease, liver disease, chronic pulmonary disease, rheumatic disease, a history of smoking, and statin use. Estimates for the primary endpoint were derived using a timeto-first-event analysis. The 10-year risk for cardiovascular events was calculated by dividing the number of patients who experienced cardiovascular events by the sum of the follow-up duration. Restricted cubic splines were constructed to evaluate the non-linear relationship between BP and cardiovascular outcomes. A two-sided P-value <0.05 was considered statistically significant. All statistical analyses were performed with R programming version 3.2.4 (http://www.R-project.org; The R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics of the study population
A total of 290 600 subjects who were naïve to antihypertensive medical treatment and who had available BP measurements were identified. The mean age was 53.6 ± 9.3 years and 58.1% were male. The mean systolic and diastolic BPs were 126.0 ± 16.7 mmHg and 79.0 ± 10.9 mmHg, respectively. Table 1 shows that the study population had a low prevalence of comorbidities.
After a median follow-up of 6.7 years with no antihypertensive medical treatment, 10 710 major cardiovascular events occurred (estimated 10-year event rate, 5.7%): 2726 cardiac death, 5688 stroke, 2276 myocardial infarction, and 2971 heart failure.
Relationship between blood pressure and cardiovascular outcomes Figure 1 shows the distribution of the baseline systolic and diastolic BP and its relationship with the risk of cardiovascular events. The relationship was linear above a BP of 115/75 mmHg, below which the CIs were wide because of the small sample size. Kaplan-Meier survival curves free from cardiovascular events according to baseline BP are shown in Figure 2 . The positive relationship was consistent across various age subgroups, while there was a tendency towards flattening of BP effects with advanced age (Figure 3) . Table 2 details event rates and HRs according to systolic and diastolic BP. Cardiovascular risk was lowest at a systolic BP of 90-99 mmHg. When unadjusted, cardiovascular risk increased approximately two-fold with a 20 mmHg increase in systolic BP (HR 1.99; 95% CI 1.95-2.03) and a 20 mmHg increase in diastolic BP (HR 2.08; 95% CI 2.01-2.16). The differences were attenuated after adjusting for age and sex. While the difference was still significant among the systolic BP categories, it lost statistical significance with a diastolic BP of <80 mmHg. Multivariable adjustment yielded similar results.
A very small number of subjects (n = 608, 0.21% of the study population) had an extremely low systolic BP (<90 mmHg). Their cardiovascular risk was comparable to that of those with a systolic BP of 120-129 mmHg and was significantly higher than that of those with a systolic BP of 90-99 mmHg and 100-109 mmHg. Similarly, 24 subjects (0.01%) had a diastolic BP <40 mmHg who had a significantly higher risk than those with a diastolic BP of 40-49 mmHg. Supplementary material online, Table S1 shows the risk when subjects with an extremely low BP were not classified separately. Analyses for each component of major cardiovascular events are shown in Supplementary material online, Tables S2 and S3.
Interplay of systolic and diastolic blood pressure in cardiovascular risk prediction Systolic and diastolic BPs were highly correlated each other (R 2 = 0.593) (Take home figure) . The slope was 0.5, i.e. a 20 mmHg increase in systolic BP was correlated with a 10 mmHg increase in diastolic BP. The fitted line crossed 120/76 mmHg, 130/81 mmHg, and 140/86 mmHg. The numbers in the scatter plot indicate estimated 10-year rates of major cardiovascular events. An increase in systolic BP was associated with higher event rates regardless of diastolic BP. The association of diastolic BP was inconsistent when stratified by systolic BP. Specifically, a diastolic BP of 80-89 mmHg was not necessarily associated with a higher risk than a diastolic BP of <80 mmHg. This inconsistency was largely attributable to the distribution of age and sex. Supplementary material online, Table S4 shows event rates stratified by age and sex. A U-shaped or inverse relationship was present among men with 55 years or older. In contrast, among women and young men, diastolic BP generally showed a positive risk prediction. Figure 4 shows a multivariable adjusted risk of diastolic BP stratified by systolic BP. Unadjusted analysis showed that diastolic BP had an inverse relationship among those with systolic BP of 140 mmHg or above, which was largely attenuated after adjustment for age and sex. While diastolic BP generally increased cardiovascular risks in a linear pattern, the difference between <80 mmHg and 80-89 mmHg was mostly non-significant.
In a line, a higher pulse pressure was associated with a higher risk for cardiovascular events among men aged 55 years or older (Supplementary material online, Table S5 and Figure S1A ). Among other subgroups, the association between pulse pressure and cardiovascular risk was not consistent. The impact of pulse pressure was mostly attenuated after adjustment for age and sex (Supplementary material online, Figure S1B and C).
Safety
Both low and high BPs were associated with increased risk of syncope and hip fracture (Supplementary material online, Tables S6 and S7). The unadjusted risk of syncope was lowest at a systolic BP of 110-119 mmHg and a diastolic BP of 80-89 mmHg, while that of hip fracture was at 110-119 mmHg and 70-79 mmHg. Although multivariable adjustment attenuated the risk estimates, the relationships remained U-shaped. log-linear manner regardless of diastolic BP, the association of diastolic BP independent of systolic BP was variable. While a wider pulse pressure was important among men aged 55 years or older, diastolic BP showed better prediction in other age and sex groups. The difference between diastolic BPs of 80-89 mmHg and <80 mmHg was small, especially in subjects with a systolic BP of <130 mmHg across different age and sex subgroups. There were few subjects with a systolic BP of <90 mmHg and a diastolic BP of <40 mmHg in this study. Although they had a significantly higher risk than those with optimal BP, they accounted for a very small proportion among ambulatory, non-institutionalized subjects, and their risk was not as high as that of those with a BP of >130/90 mmHg. In accordance with previous studies, we also found that cardiovascular risk increases in a log-linear manner with systolic and diastolic BP. A previous meta-analysis showed that each 20-mmHg difference of the usual systolic BP (or 10 mmHg of the usual diastolic BP) was associated with about a two-fold increased risk for stroke and vascular mortality, without a definite threshold down to at least 115/ 75 mmHg. 5 However, the clinical significance of diastolic BP independent of systolic BP has been questioned. 12, 13 An analysis from the BP, blood pressure; HF, heart failure; MI, myocardial infarction.
Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events Framingham Heart Study showed that the importance as cardiovascular risk predictors shifts from diastolic BP, to systolic BP, and to pulse pressure with increasing age. This study also showed that the association between diastolic BP and cardiovascular risk was positive when considered separately, but inconsistent when stratified by systolic BP. This discrepancy was largely due to the different BP distribution and risk profiles across age and sex. For elderly men who had the highest event rates, an increase in pulse pressure rather than diastolic BP relevantly accounted for cardiovascular risk. For other age and sex groups, diastolic BP generally showed a positive relationship. For most subgroups, the gap in the risk between a diastolic BP of 80-89 mmHg and <80 mmHg was either numerically small or even inverse. Recently, the 2017 ACC/AHA Guidelines for high BP lowered the threshold of hypertension definition from 140/90 mmHg to 130/ 80 mmHg. 7 According to the guideline, subjects with a systolic BP be- and sex-adjusted, and (C) multivariable-adjusted hazard ratios for major cardiovascular events by systolic blood pressure group in each diastolic blood pressure group. CI, confidence intervals; SBP, systolic blood pressure.
Reconsidering the cut-off diastolic blood pressure for predicting cardiovascular events However, this study raises concerns regarding the diastolic BP criteria of > _80 mmHg in the 2017 ACC/AHA guideline. Controversies exist regarding the inclusion of diastolic BP in the definition of hypertension. 15, 23, 24 Results from randomized controlled trials support lowering the systolic BP criteria to > _130 mmHg. The SPRINT (Systolic Blood Pressure Intervention Trial) enrolled subjects with a systolic BP of 130 mmHg or higher and demonstrated the benefit of intensive treatment strategy. 6 However, there is insufficient evidence supporting the use of diastolic BP as a criterion for defining hypertension. Most randomized trials enrolled patients based on systolic BP alone. 6, 20, 25 The ABCD trial (Appropriate Blood Pressure Control in Diabetes) is the only trial that defined hypertension as a diastolic BP of 90 mmHg or higher. 26, 27 This study showed that cardiovascular risk with a systolic BP of > _130 mmHg corresponds better with a diastolic BP of > _90 mmHg rather than with that of > _80 mmHg. The risk increased sharply over 90 mmHg when stratified by age, sex, and systolic BP. In addition, the difference between diastolic BPs of <80 mmHg and 80-89 mmHg mostly disappeared after statistical adjustment. As implied in this study, a person classified as having Stage 1 'isolated diastolic' hypertension by the new guideline (systolic BP <130 mmHg and diastolic BP 80-89 mmHg) may not have elevated cardiovascular risk compared to normotensive patients across any age and sex subgroups (Supplementary material online, Table S8 and Figure S2 ). It has been debated whether a J-curve association exists between untreated BP and cardiovascular risks. 10 The concept of the J-curve phenomenon is used mixedly in the literature. The issue was first raised in hypertension treatment with concerns that lowering BP to a certain level may lead to worse outcomes. 28, 29 Several studies used the same term in untreated hypertension. 10, 30, 31 However, it needs to be noted that the relationship between cardiovascular risk and untreated vs. treated hypertension may differ. A low baseline BP is mostly unintentional, frequently associated with comorbid condition or frailty and is thus not relevant for cardiovascular prevention. 32 We found that the relationship was J-shaped, but the trough was located at as low as a systolic BP of 90 mmHg and a diastolic BP of 40 mmHg. Subjects with a BP of <90/40 mmHg accounted for a very small proportion of the study population (0.22%). Although their risk was higher than that of those with the most optimal BP (systolic BP 90-99 mmHg), it was still low and was similar to the risk of those between 120 mmHg and 129 mmHg, and not as high as that of hypertensive subjects. It needs to be clarified that this 'extremely low BP' phenomenon is different from the 'J-curve' phenomenon in treated hypertension and that overemphasizing this extremely rare situation may mislead 'normotensive' subjects with optimal BP to discontinue a healthy lifestyle.
Limitations
One of the major limitations was the study population of homogeneous Korean ethnicity. Korea has one of the lowest agestandardized prevalence rates of cardiovascular disease along with Japan, Italy, and Greece. 33 Aside from genetic factors, there are also distinctive lifestyle factors such as diet, physical activity, and the prevalence of metabolic syndrome. Further studies are needed to confirm whether this study findings can be generalized to other ethnic groups. Second limitation of this study was its retrospective observational design. However, the use of national registration data ensures the untreated status of the study population, the capture of study outcomes without missing, and a low chance of attrition bias. Third, there was considerable heterogeneity in BP measurement methods across institutions. This raises the possibility that the relationship of diastolic BP and pulse pressure with cardiovascular events may be biased by the measurement methods. Fourth, classification of the individuals was based on a single BP measurement. Repeated visits or ambulatory measurements have been shown to minimize the chance of misclassifications. This study also has a potential risk of bias due to white-coat effects, a phenomenon wherein a patient's BP measured in a clinic or office may be higher than their ambulatory pressure. 34 Fifth, because this study was done with the antihypertensive-naïve subjects, the results cannot be extrapolated to treated hypertension. Lastly, since operational definitions were used for baseline risk factor assessment and the occurrence of study endpoints, there is possibility of misclassifications bias.
Conclusion
Elevated BP is a strong predictor of adverse cardiovascular events including cardiac and all-cause death, myocardial infarction, stroke, and heat failure. This study showed that both systolic and diastolic BP increased cardiovascular risk in a log-linear manner. The linear relationship extended down to a systolic BP of > _90 mmHg and a diastolic BP of > _40 mmHg. The effect of diastolic BP was variable when adjusted for or stratified by systolic BP. This study implies that even at a time when hypertension is defined using a lower BP (> _130/ 80 mmHg), the diastolic component of > _80 mmHg seems disproportionately low and a diastolic cut-off of > _90 mmHg would be more appropriate.
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Supplementary material is available at European Heart Journal online.
